ClinicalTrials.gg
CompletedNCT03574415Updated Jun 27, 2019

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DWP14012 After Oral Administration in Healthy Japanese, Caucasian and Korean

A Phase 1 interventional study of DWP14012 and Placebo in Healthy Volunteers, sponsored by Daewoong Pharmaceutical Co. LTD.. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-06-27.

Sponsored by Daewoong Pharmaceutical Co. LTD. · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
19 Years to 50 Years
Sex
All
01

Study summary

To evaluate the safety and tolerability of single and multiple ascending oral doses of DWP14012 in healthy Japanese, Caucasian and Korean subjects

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Daewoong Pharmaceutical Co. LTD. is the lead sponsor of 200 studies on the registry; 33 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adult Caucasian or Japanese or Korean aged 19 to 50 (inclusive) years, at the time of screening.
  • Subjects weighing between 50 kg and 90 kg with between 18 and 27 kg/m2 (inclusive) at screening visit.

Exclusion criteria

Exclusion Criteria:

  • Those who have clinical significant liver, kidney, nervous system, respiratory, endocrine, hematology and oncology, cardiovascular, urinary, and mental diseases or past history
  • Those who have gastrointestinal diseases or past history of gastrointestinal diseases (gastrointestinal ulcer, gastritis, gastrospasm, gastroesophageal reflux, Crohn's disease etc.) that may affect safety and pharmacokinetic/pharmacodynamic evaluation of study drug, and those who have past history of gastrointestinal surgery (however, except simple appendectomy and herniotomy)
  • Those who have been Helicobacter pylori positive
  • Those whose plasma (SGOT) and ALT (SGPT) exceed 1.5 times to the in screening including additional examinations prior to randomization
  • Those who have anatomical disability in insertion and maintenance of pH meter catheter
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    Japanese_DWP14012 Amg

    DWP14012 Amg, tablets, orally, single and multiple administration

    Drug: DWP14012 · Drug: Placebo

  • Experimental
    Japanese_DWP14012 Bmg

    DWP14012 Bmg, tablets, orally, single and multiple administration

    Drug: DWP14012 · Drug: Placebo

  • Experimental
    Japanese_DWP14012 Cmg

    DWP14012 Cmg, tablets, orally, single and multiple administration

    Drug: DWP14012 · Drug: Placebo

  • Experimental
    Caucasian_DWP14012 Bmg

    DWP14012 Bmg, tablets, orally, single and multiple administration

    Drug: DWP14012 · Drug: Placebo

  • Experimental
    Caucasian_DWP14012 Cmg

    DWP14012 Cmg, tablets, orally, single and multiple administration

    Drug: DWP14012 · Drug: Placebo

  • Experimental
    Korean_DWP14012 Bmg

    DWP14012 Bmg, tablets, orally, single and multiple administration

    Drug: DWP14012 · Drug: Placebo

  • Experimental
    Korean_DWP14012 Cmg

    DWP14012 Cmg, tablets, orally, single and multiple administration

    Drug: DWP14012 · Drug: Placebo

  • Placebo comparator
    Placebo

    DWP14012 placebo-matching tablets

    Drug: Placebo

Interventions

  • DWP14012 tablets

  • DrugPlacebo

    DWP14012 placebo-matching tablets

06

What researchers measure

Primary outcomes

  1. Cmax

    Maximum concentration of DWP14012

    Time frame: 1d pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 5d~10d pre-dose, 11d pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96h

  2. Cmax,ss / Cmin,ss

    Maximum / Minimum concentration of DWP14012 at steady state

    Time frame: 1d pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 5d~10d pre-dose, 11d pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96h

  3. Tmax

    Time of maximum concentration

    Time frame: 1d pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 5d~10d pre-dose, 11d pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96h

  4. AUClast / AUCinf

    Area under the plasma concentration-time curve

    Time frame: 1d pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 5d~10d pre-dose, 11d pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96h

  5. T1/2

    Elimination half-life

    Time frame: 1d pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 5d~10d pre-dose, 11d pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96h

  6. Percentage of total time that the intragastric pH was above 4

    After single administration of the investigational products, 24hr gastric pH monitoring started.

    Time frame: Day 1

  7. Percentage of total time that the intragastric pH was above 4

    After single administration of the investigational products, 24hr gastric pH monitoring started.

    Time frame: Day 7

07

Study locations

1 site
  • Seoul National University Hospital
    Seoul, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2018 to primary completion in Jan 2019, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2018
First posted
Jul 2, 2018
StartActual
Nov 1, 2018
Primary completionActual
Jan 18, 2019
CompletionActual
Jan 23, 2019
Last update
Jun 27, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 27, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03574415
Responsible party
Sponsor
First posted
Jul 2, 2018
Start date
Nov 1, 2018
Primary completion
Jan 18, 2019
Completion
Jan 23, 2019
Last update
Jun 27, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fexuprazan

Start the discussion